StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Vaccines & Immune Therapies / Infectious Disease by Year

Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY actual (%) (%)

AstraZeneca Vaccines & Immune Therapies / Infectious Disease: -60.0% in FY2025, down 13.0 pts from a year earlier.

Latest, FY2025
-60.0%
Period ended Dec 31, 2025
Change on a year earlier
-13.0 pts
-47.0% in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below

Where the FY2025 figure comes from

“|| V&I | 846 | (20) | (20) | 209 | (26) | 220 | 3 | 5 | 354 | (13) | (15) | 63 | (60) | (60)”

Source: Form 6-K FY2025Q4 Earnings Release ↗

Reported in Form 6-K / 20-F Therapy Area Product Sales Table.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY actual (%) (%)Year on yearSource
FY2025Dec 31, 2025-60.0%-13.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
FY2024Dec 31, 2024-47.0%+29.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
FY2023Dec 31, 2023-76.0%-144.0 ptsForm 6-K FY2023Q4 Earnings Release ↗
FY2022Dec 31, 202268.0%–Form 6-K FY2022Q4 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Vaccines & Immune Therapies / Infectious Disease (%), annual FY2022–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-vi-erow-act-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.